Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Diabetes type1: early-phase trial registry

4 of 5 indexed Diabetes type1 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Diabetes type1: 5 US clinical trials tracked, 4 recruiting.

Diabetes type1 is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition diabetes-type1

OPEN 4 | RECR 80% | LATE 1 | EARLY 3 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Diabetes type1 (this)80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Diabetes type1

Diabetes type1 lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetes type1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetes type1 is recruiting above its size-band peers.

    4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Diabetes type1 research.

    Massachusetts General Hospital accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetes type1 enrolment sits around 100 participants.

    Median target enrolment is 100 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Diabetes type1 research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 23Phase 31

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Diabetes type1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Saline Injection Biological
2 trials
Bacillus Calmette-Guérin Biological
2 trials
LY900014 Drug
1 trials
Insulin lispro Drug
1 trials
TakeCharge Behavioral
1 trials
ReCharge Behavioral
1 trials
Semaglutide Pen Injector Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Diabetes type1 trials. A trial with sites in several states counts in each.

Massachusetts 2 trials
North Carolina 1 trials
Georgia 1 trials
Connecticut 1 trials
Colorado 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetes type1 page

5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes type1 condition card totals 5 registered trials; most-linked intervention Saline Injection; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.